A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Prior treatment

• Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening)
• Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
• Any previous or planned surgery for sleep apnea or major ear, nose or throat surgery that still may affect breathing at time of screening
• Have had within 90 days prior to screening:
  • acute myocardial infarction
  • cerebrovascular accident (stroke)
  • coronary artery revascularization
  • unstable angina, or
  • hospitalization due to congestive heart failure
• Have taken medications or alternative remedies intended for weight loss within 90 days of screening

Other illness

• Have type 1 diabetes, type 2 diabetes, or any other type of diabetes
• Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure

• Confirmed history of moderate-to-severe OSA
• Have an AHI ≥ 15 on polysomnography (PSG) as part of the study at screening
• Have a BMI ≥27 kg/m2 at screening
• Have a stable body weight (\<5% body weight change) for 90 days prior to screening
• Have a history of at least one self-reported unsuccessful dietary effort to reduce body weight
  • For YSA1 Participants:
• Are unable or unwilling to use PAP therapy
  • For YSA2 Participants:
• Have been on PAP therapy for at least three consecutive months prior to screening and plan to continue PAP therapy during the study